Diane-35 (cyproterone acetate): safety concerns

about

Cyproterone acetate-ethinyl estradiol use in a 23-year-old woman with stroke.Medicine by media: did a critical television documentary affect the prescribing of cyproterone--estradiol (Diane-35)?Examining the use of oral contraceptives in the management of acne.First-use risks.

P2860

Q33728471-B6846774-D2B8-4154-902D-08163431BBD8 Q34132570-4A164C95-46F1-4CB2-8407-6CC037059765 Q34272111-B97B80E9-B8EE-4167-8761-7030575EC525 Q42867616-893874A4-87C0-4737-9F96-ADA3947BC31D

P2860

Diane-35 (cyproterone acetate): safety concerns

Item

http://www.wikidata.org/entity/Q34536900

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Diane-35 (cyproterone acetate): safety concerns

@ast

Diane-35 (cyproterone acetate): safety concerns

@en

Diane-35

@nl

type

Item

label

Diane-35 (cyproterone acetate): safety concerns

@ast

Diane-35 (cyproterone acetate): safety concerns

@en

Diane-35

@nl

prefLabel

Diane-35 (cyproterone acetate): safety concerns

@ast

Diane-35 (cyproterone acetate): safety concerns

@en

Diane-35

@nl

P1476

Diane-35 (cyproterone acetate): safety concerns

@en

P2093

Eric Wooltorton

http://www.w3.org/2001/XMLSchema#string

P2860

Third generation oral contraceptives and risk of venous thrombosis: meta-analysis

Oral contraceptives and myocardial infarction.

The effect of factor V Leiden carriage on maternal and fetal health

Oral contraceptives and the risk of venous thrombosis.

Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.

Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Third generation oral contraceptives.

Guidelines for prescribing combined oral contraceptives.

Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.

Oral contraceptives and venous thromboembolism: a five-year national case-control study.

P304

455-456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

168

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12591790

http://www.w3.org/2001/XMLSchema#string

P932

143555

http://www.w3.org/2001/XMLSchema#string

Diane-35 (cyproterone acetate): safety concerns

about

P2860

P2860

Diane-35 (cyproterone acetate): safety concerns

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P932